One of the major opportunities in healthcare today is disrupting the status quo in pharmaceuticals. Hims & Hers (NYSE: HIMS) has brought a new model to the market and is growing extremely rapidly while becoming a go-to platform for millions of users.
*Stock prices used were end-of-day prices of Oct. 28, 2024. The video was published on Oct. 30, 2024.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,217!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,153!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $403,994!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
See 3 “Double Down” stocks »
*Stock Advisor returns as of October 28, 2024
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.